TIVA for Cleft Lip-Palate Repair in Infants
For cleft lip-palate repair in infants aged 2-12 months, use propofol-based TIVA with remifentanil, combined with bilateral infraorbital nerve blocks and multimodal analgesia (paracetamol + NSAID), with mandatory pulse oximetry monitoring and processed EEG when neuromuscular blockade is used.
Anesthetic Technique
Induction and Maintenance
Propofol with remifentanil is the preferred TIVA combination for this population 1, 2. The technique requires:
- Propofol: Target effect-site concentration of 3-4 mcg/mL for induction, 2.5-3.5 mcg/mL for maintenance using target-controlled infusion (TCI) with pediatric models (Kataria or Absalom) 2
- Remifentanil: Effect-site target of 2-4 ng/mL, titrated to surgical stimulation 2
- Early down-titration is critical in this age group to prevent excessive depth and respiratory depression 1
For infants under 6 months or weighing <5 kg, use lower initial targets and titrate cautiously due to immature hepatic metabolism and higher free drug fractions 3.
Muscle Relaxation
Use rocuronium 0.6-0.9 mg/kg for intubation 4. In infants, succinylcholine dosing is age-specific: 1.8 mg/kg for <1 month, 2 mg/kg for 1-12 months 4, though rocuronium is increasingly preferred to avoid malignant hyperthermia risk.
Airway Management
Orotracheal intubation is required for palate repair 5. These infants have anatomical challenges including:
- Distorted nasal anatomy
- Potential difficult airway from associated syndromes
- Risk of airway obstruction postoperatively
Critical Monitoring Requirements
Mandatory Monitoring
Per 2021 Association of Anaesthetists guidelines 6:
- Pulse oximetry with plethysmograph (essential)
- Non-invasive blood pressure
- ECG
- Temperature (before anesthesia, then every 30 minutes)
- Waveform capnography
- Inspired/expired oxygen concentration
Enhanced Monitoring for TIVA
When using neuromuscular blockade with TIVA, processed EEG monitoring is mandatory 6, 7. This prevents awareness and guides appropriate depth, particularly critical in infants where clinical signs are unreliable. Bispectral index (BIS) or entropy monitoring should target 40-60 7, 8.
Quantitative neuromuscular monitoring is required throughout when muscle relaxants are used 6.
Multimodal Analgesia Strategy
The 2024 ESPA guidelines provide a tiered approach specifically for cleft surgery 9:
Regional Anesthesia (Advanced Level)
Bilateral infraorbital nerve blocks with long-acting local anesthetic (ropivacaine 0.2% at 0.5-1 mg/kg per side) 9. This is the cornerstone technique that can eliminate intraoperative opioid requirements when combined with non-opioids 9.
Non-Opioid Analgesics
Administer both agents for opioid-sparing effect 9:
- Paracetamol: 15 mg/kg IV or 30-40 mg/kg rectal
- NSAID: Ibuprofen 10 mg/kg rectal or IV ketorolac 0.5 mg/kg (if >6 months)
The combination significantly reduces opioid requirements and is particularly valuable when IV rescue is unavailable 9.
Adjunctive Agents
Dexamethasone 0.15 mg/kg IV (max 8 mg) reduces postoperative swelling and prolongs block duration 9. This is particularly important in cleft surgery where airway edema is a concern.
Intraoperative ketamine (0.25-0.5 mg/kg bolus) or dexmedetomidine (0.5-1 mcg/kg) provide opioid-sparing effects and reduce emergence delirium 9, 1.
Opioid Management
If regional block fails or for breakthrough pain:
- Intraoperative: Fentanyl 1-2 mcg/kg divided doses 9
- PACU: Fentanyl titrated to effect
- Ward: In infants, nalbuphine is preferred over other opioids for rescue analgesia 9
Critical caveat: Avoid excessive intraoperative opioids as they increase respiratory complications and PONV in this vulnerable population 9.
Drug Delivery Safety
Infusion Setup
- Use dedicated IV line with anti-siphon valves
- Enable all pump alarms (high pressure, occlusion, empty syringe, disconnection) 6
- Visualize the IV cannula throughout the procedure when possible 6
- Label all syringes clearly with drug name and concentration 10
Pharmacokinetic Considerations
Ropivacaine dosing for regional blocks in infants <6 months: maximum 2 mg/kg due to reduced clearance 3. For infants >6 months, up to 2.5 mg/kg is acceptable 3.
Propofol infusion syndrome is exceedingly rare but avoid prolonged high-dose infusions (>4 mg/kg/h for >48 hours) 1, 7.
Postoperative Management
Immediate Recovery (PACU)
- Continue pulse oximetry monitoring for at least 24 hours 9
- IV fentanyl available for breakthrough pain
- Monitor for airway obstruction from surgical edema
Ward Management
- Scheduled non-opioids: Continue paracetamol + NSAID around-the-clock 9
- Rescue analgesia: Oral/IV nalbuphine or tramadol as needed 9
- Transition to oral administration as soon as tolerated
- If metamizole is available, use as first-line rescue 9
Special Considerations for This Population
Cleft-Specific Issues
Nearly all infants with cleft palate have chronic middle ear effusion and eustachian tube dysfunction 11. This increases:
- Risk of aspiration
- Hearing loss requiring audiologic follow-up
- Need for coordinated multidisciplinary care 12
High-Risk Features
Infants with cleft palate may have associated syndromes (Pierre Robin, Down syndrome) requiring:
- More careful airway assessment
- Consideration of fiberoptic intubation availability
- Awareness of cardiac or other congenital anomalies 12
Environmental Considerations
TIVA produces substantially lower greenhouse gas emissions than volatile anesthesia, an additional benefit without compromising patient care 1.
Common Pitfalls to Avoid
- Inadequate depth monitoring: Never use TIVA with muscle relaxants without processed EEG in infants 6, 7
- Excessive opioids: Regional blocks + non-opioids can eliminate intraoperative opioid needs 9
- Forgetting dexamethasone: Critical for reducing airway edema in this surgery 9
- Inadequate postoperative monitoring: Minimum 24 hours pulse oximetry required 9
- IV line failure: This is catastrophic in TIVA—secure access and maintain visibility 6